International Journal of Obstetric Anesthesia
Volume 19, Issue 3 , Pages 313-319 , July 2010

The use of uterotonic drugs during caesarean section

,Accepted 22 April 2010.

References 

  1. Clyburn P, Morris S, Hall J. Anaesthesia and safe motherhood. Anaesthesia. 2007;62(Suppl 1):21–25
  2. Arias F. Pharmacology of oxytocin and prostaglandins. Clin Obstet Gynecol. 2000;43:455–468
  3. Garfield RE, Kannan MS, Daniel EE. Gap junction formation in myometrium: control by estrogens, progesterone, and prostaglandins. Am J Physiol. 1980;238:C81–C89
  4. Gutkowska J, Jankowski M, Lambert C, Mukaddam-Daher S, Zingg HH, McCann SM. Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proc Natl Acad Sci USA. 1997;94:11704–11709
  5. Jankowski M, Hajjar F, Kawas SA, et al. Rat heart: a site of oxytocin production and action. Proc Natl Acad Sci USA. 1998;95:14558–14563
  6. Mukaddam-Daher S, Yin YL, Roy J, Gutkowska J, Cardinal R. Negative inotropic and chronotropic effects of oxytocin. Hypertension. 2001;38:292–296
  7. Rosaeg OP, Cicutti NJ, Labow RS. The effect of oxytocin on the contractile force of human atrial trabeculae. Anesth Analg. 1998;86:40–44
  8. Bergum D, Lonnee H, Hakli TF. Oxytocin infusion: acute hyponatraemia, seizures and coma. Acta Anaesthesiol Scand. 2009;53:826–827
  9. Weis FR, Markello R, Mo B, Bochiechio P. Cardiovascular effects of oxytocin. Obstet Gynecol. 1975;46:211–214
  10. Secher NJ, Arnsbo P, Wallin L. Haemodynamic effects of oxytocin (syntocinon) and methyl ergometrine (methergin) on the systemic and pulmonary circulations of pregnant anaesthetized women. Acta Obstet Gynecol Scand. 1978;57:97–103
  11. Langesaeter E, Rosseland LA, Stubhaug A. Hemodynamic effects of oxytocin during cesarean delivery. Int J Gynaecol Obstet. 2006;95:46–47
  12. Dyer RA, Reed AR, van Dyk D, et al. Hemodynamic effects of ephedrine, phenylephrine and the coadministration of phenylephrine and oxytocin during spinal anesthesia for elective cesarean section. Anesthesiology. 2009;111:753–765
  13. Archer TL, Knape K, Liles D, Wheeler AS, Carter B. The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery. Int J Obstet Anesth. 2008;17:247–254
  14. Pinder AJ, Dresner M, Calow C, Shorten GD, O’Riordan J, Johnson R. Haemodynamic changes caused by oxytocin during caesarean section under spinal anaesthesia. Int J Obstet Anesth. 2002;11:156–159
  15. Dyer RA, Piercy JL, Reed AR, Lombard CJ, Schoeman LK, James MF. Hemodynamic changes associated with spinal anesthesia for cesarean delivery in severe preeclampsia. Anesthesiology. 2008;108:802–811
  16. Thomas TA, Cooper GM. Maternal deaths from anaesthesia. An extract from why mothers die 1997–1999, the confidential enquiries into maternal deaths in the United Kingdom. Br J Anaesth. 2002;89:499–508
  17. Lamacraft G. Anaesthesia related deaths. In Pattinson RC, ed. Saving mothers: fourth report on confidential enquiries into maternal deaths in South Africa. Department of Health, Pretoria, Republic of South Africa 2010: 137.
  18. Fortner CL, Manley ES, Woodbury RA. Effects of synthetic oxytocin with and without preservatives upon coronary blood flow in the dog. J Pharmacol Exp Ther. 1969;165:258–266
  19. Svanstrom MC, Biber B, Hanes M, Johansson G, Naslund U, Balfors EM. Signs of myocardial ischaemia after injection of oxytocin: a randomized double-blind comparison of oxytocin and methylergometrine during Caesarean section. Br J Anaesth. 2008;100:683–689
  20. Dogan R, Birdane A, Bilir A, Ekemen S, Tanriverdi B. Frequency of electrocardiographic changes indicating myocardial ischemia during elective cesarean delivery with regional and general anesthesia: detection based on continuous Holter monitoring and serum markers of ischemia. J Clin Anesth. 2008;20:347–351
  21. Jonsson M, Hanson U, Lidell C, Norden-Lindeberg S. ST depression at caesarean section and the relation to oxytocin dose. A randomised controlled trial. BJOG. 2010;117:76–83
  22. Sartain JB, Barry JJ, Howat PW, McCormack DI, Bryant M. Intravenous oxytocin bolus of 2 units is superior to 5 units during elective Caesarean section. Br J Anaesth. 2008;101:822–826
  23. Thomas JS, Koh SH, Cooper GM. Haemodynamic effects of oxytocin given as i.v. bolus or infusion on women undergoing Caesarean section. Br J Anaesth. 2007;98:116–119
  24. Langesaeter E, Dragsund M, Rosseland LA. Regional anaesthesia for a Caesarean section in women with cardiac disease: a prospective study. Acta Anaesthesiol Scand. 2010;54:46–54
  25. Carvalho JC, Balki M, Kingdom J, Windrim R. Oxytocin requirements at elective cesarean delivery: a dose-finding study. Obstet Gynecol. 2004;104:1005–1010
  26. Butwick AJ, Coleman L, Cohen SE, Riley ET, Carvalho B. Minimum effective bolus dose of oxytocin during elective caesarean delivery. Br J Anaesth. 2010;104:338–343
  27. Balki M, Ronayne M, Davies S, et al. Minimum oxytocin dose requirement after cesarean delivery for labor arrest. Obstet Gynecol. 2006;107:45–50
  28. Abdul-Karim R, Assali NS. Renal function in human pregnancy. V. Effects of oxytocin on renal hemodynamics and water and electrolyte excretion. J Lab Clin Med. 1961;57:522–532
  29. George RB, McKeen D, Chaplin AC, McLeod L. Up-down determination of the ED90 of oxytocin infusions for the prevention of postpartum uterine atony in parturients undergoing Cesarean delivery. Can J Anesth, in press.
  30. Royal College of Obstetricians and Gynaecologists. Prevention and treatment of postpartum haemorrhage Royal College of Obstetricians and Gynaecologists’ Green-top Guideline no.52, 2009. http://www.rcog.org.uk.
  31. Langesaeter E, Rosseland LA, Stubhaug A. Haemodynamic effects of repeated doses of oxytocin during Caesarean delivery in healthy parturients. Br J Anaesth. 2009;103:260–262
  32. Phaneuf S, Rodriguez LB, TambyRaja RL, MacKenzie IZ, Lopez BA. Loss of myometrial oxytocin receptors during oxytocin-induced and oxytocin-augmented labour. J Reprod Fertil. 2000;120:91–97
  33. Magalhaes JK, Carvalho JC, Parkes RK, Kingdom J, Li Y, Balki M. Oxytocin pretreatment decreases oxytocin-induced myometrial contractions in pregnant rats in a concentration-dependent but not time-dependent manner. Reprod Sci. 2009;16:501–508
  34. Balki M, Cristian A, Parkes RK, Kingdom J, Carvalho JC. Oxytocin preexposure of pregnant rat myometrium reduces the efficacy of oxytocin but not of ergonovine or carboprost. Washington, USA: Society of Obstetric Anesthesia and Perinatology Annual Meeting; 2009. A12.
  35. Brindlye BA, Sokol RJ. Induction and augmentation: basis and methods for current practice. Obstet Gynecol Surv. 1988;43:730–743
  36. Sweeney G, Holbrook AM, Levine M, et al. Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, in non-pregnant women. Curr Ther Res. 1990;47:520–540
  37. Rath W. Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin. Eur J Obstet Gynecol Reprod Biol. 2009;147:15–20
  38. Dansereau J, Joshi AK, Helewa ME, et al. Double-blind comparison of carbetocin versus oxytocin in preventing uterine atony post caesarean section. Am J Obstet Gynecol. 1999;180:670–676
  39. van Dongen PW, Verbruggen MM, de Groot AN, van Roosmalen J, Sporken JM, Schulz M. Ascending dose tolerance study of intramuscular carbetocin administered after normal vaginal birth. Eur J Obstet Gynecol Reprod Biol. 1998;77:181–187
  40. Su LL, Chong YS, Samuel M. Oxytocin agonists for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2007;(Art. No.: CD005457)
  41. Vercauteren M, Palit S, Soetens F, Jacquemyn Y, Alahuhta S. Anaesthesiological considerations on tocolytic and uterotonic therapy in obstetrics. Acta Anaesthesiol Scand. 2009;53:701–709
  42. den Hertog CE, de Groot AN, van Dongen PW. History and use of oxytocics. Eur J Obstet Gynecol Reprod Biol. 2001;94:8–12
  43. de Groot AN, van Dongen PW, Vree TB, Hekster YA, van Roosmalen J. Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs. 1998;56:523–535
  44. Lin YH, Seow KM, Hwang JL, Chen HH. Myocardial infarction and mortality caused by methylergonovine. Acta Obstet Gynecol Scand. 2005;84:1022
  45. Hayashi Y, Ibe T, Kawato H, et al. Postpartum acute myocardial infarction induced by ergonovine administration. Intern Med. 2003;42:983–986
  46. World Health Organisation. WHO Guidelines for the Management of Postpartum Haemorrhage and Retained Placenta, 2009. http://whqlibdoc.who.int/publications/2009/9789241598514_eng.pdf.
  47. Balki M, Carvalho JC. Intraoperative nausea and vomiting during cesarean section under regional anesthesia. Int J Obstet Anesth. 2005;14:230–241
  48. Myerscough PR, Schild H. Quantitative assays of oxytocic drugs on the human postpartum uterus. Br J Pharmacol Chemother. 1958;13:207–212
  49. Takagi S, Yoshida T, Togo Y, et al. The effects of intramyometrial injection of prostaglandin F2alpha on severe post-partum hemorrhage. Prostaglandins. 1976;12:565–579
  50. Corson SL, Bolognese RJ. Postpartum uterine atony treated with prostaglandins. Am J Obstet Gynecol. 1977;129:918–919
  51. Hayashi RH, Castillo MS, Noah ML. Management of severe postpartum hemorrhage due to uterine atony using an analogue of prostaglandin F2 alpha. Obstet Gynecol. 1981;58:426–429
  52. Harber CR, Levy DM, Chidambaram S, Macpherson MB. Life-threatening bronchospasm after intramuscular carboprost for postpartum haemorrhage. BJOG. 2007;114:366–368
  53. Andersen LH, Secher NJ. Pattern of total and regional lung function in subjects with bronchoconstriction induced by 15-me PGF2 alpha. Thorax. 1976;31:685–692
  54. Chou MM, MacKenzie IZ. A prospective, double-blind, randomized comparison of prophylactic intramyometrial 15-methyl prostaglandin F2 alpha, 125 micrograms, and intravenous oxytocin, 20 units, for the control of blood loss at elective cesarean section. Am J Obstet Gynecol. 1994;171:1356–1360
  55. Granstrom L, Ekman G, Ulmsten U. Intravenous infusion of 15 methyl-prostaglandin F2 alpha (Prostinfenem) in women with heavy post-partum hemorrhage. Acta Obstet Gynecol Scand. 1989;68:365–367
  56. Secher NJ, Thayssen P, Arnsbo P, Olsen J. Effect of prostaglandin E2 and F2alpha on the systemic and pulmonary circulation in pregnant anesthetized women. Acta Obstet Gynecol Scand. 1982;61:213–218
  57. Hofmeyr GJ, Gulmezoglu AM. Misoprostol for the prevention and treatment of postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol. 2008;22:1025–1041
  58. Hofmeyr GJ, Gulmezoglu AM, Novikova N, Linder V, Ferreira S, Piaggio G. Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects. Bull World Health Organ. 2009;87:666–677
  59. O’Brien P, El Refaey H, Gordon A, Geary M, Rodeck CH. Rectally administered misoprostol for the treatment of postpartum hemorrhage unresponsive to oxytocin and ergometrine: a descriptive study. Obstet Gynecol. 1998;92:212–214
  60. Hamm J, Russell Z, Botha T, Carlan SJ, Richichi K. Buccal misoprostol to prevent hemorrhage at cesarean delivery: a randomized study. Am J Obstet Gynecol. 2005;192:1404–1406
  61. Acharya G, Al Sammarai MT, Patel N, Al Habib A, Kiserud T. A randomized, controlled trial comparing effect of oral misoprostol and intravenous syntocinon on intra-operative blood loss during cesarean section. Acta Obstet Gynecol Scand. 2001;80:245–250
  62. Ramsey PS, Hogg BB, Savage KG, Winkler DD, Owen J. Cardiovascular effects of intravaginal misoprostol in the mid trimester of pregnancy. Am J Obstet Gynecol. 2000;183:1100–1102
  63. Blum J, Winikoff B, Raghavan S, et al. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial. Lancet. 2010;375:217–223
  64. Beukens P, Althabe F. Post-partum haemorrhage: beyond the confrontation between misoprostol and oxytocin. Lancet. 2010;375:176–178
  65. Writer WD, Baskett TF. Postpartum hemorrhage. In:  Datta S editors. Anesthetic and obstetric management of high-risk pregnancy. 2nd ed.. St Louis: Mosby; 1996;p. 110–113
  66. Moodie JE, Moir DD. Ergometrine, oxytocin and extradural analgesia. Br J Anaesth. 1976;48:571–574
  67. McDonald S, Abbott JM, Higgins SP. Prophylactic ergometrine–oxytocin versus oxytocin for the third stage of labour. Cochrane Database Syst Rev. 2004;(CD000201)

PII: S0959-289X(10)00059-2

doi: 10.1016/j.ijoa.2010.04.011

International Journal of Obstetric Anesthesia
Volume 19, Issue 3 , Pages 313-319 , July 2010

Article Tools

* Image Usage & Resolution